Stockscreener 앱 받기
4.99
3.31%
0.16
시간 외 거래:
4.88
-0.11
-2.20%
전일 마감가:
$4.83
열려 있는:
$4.82
하루 거래량:
384.96K
Relative Volume:
1.26
시가총액:
$288.54M
수익:
-
순이익/손실:
$-40.33M
주가수익비율:
-0.8358
EPS:
-5.97
순현금흐름:
$-39.53M
1주 성능:
+39.00%
1개월 성능:
+90.46%
6개월 성능:
+107.05%
1년 성능:
+305.69%
1일 변동 폭
$4.7577
$5.38
1주일 범위
$3.50
$5.54
52주 변동 폭
$1.07
$5.54
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
명칭
Eledon Pharmaceuticals Inc
전화
949-238-8090
주소
19800 MACARTHUR BLVD., IRVINE
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-05-13 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-03-23 | 개시 | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc 주식(ELDN)의 최신 뉴스
Biotechnology Value Fund L P's Strategic Acquisition in Eledon P - GuruFocus.com
ELDN stock touches 52-week high at $4.13 amid robust gains - Investing.com Australia
ELDN stock touches 52-week high at $4.13 amid robust gains By Investing.com - Investing.com South Africa
SEC Form 424B5 filed by Eledon Pharmaceuticals Inc. - Quantisnow
Eledon drug helps transplants 'cure' type 1 diabetes - pharmaphorum
Eledon Pharmaceuticals sets terms for $85 million stock offering By Investing.com - Investing.com South Africa
Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart (ELDN) - Seeking Alpha
Eledon Pharmaceuticals Shares Hit 52-Week High After Positive Trial Data - MarketWatch
Promising results for diabetes treatment with new drug By Investing.com - Investing.com Australia
Eledon Pharmaceuticals sets terms for $85 million stock offering - Investing.com India
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine - The Manila Times
Promising results for diabetes treatment with new drug - Investing.com India
Eledon Pharmaceuticals Announces Pricing of $85 Million - GlobeNewswire
Eledon Pharmaceuticals Announces Positive Initial Data from - GlobeNewswire
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - StockTitan
Algorae Pharmaceuticals Plans Major Securities Issuance - MSN
Midday Stock Roundup: The Ensign Group Beats Q3 Expectations - Orange County Business Journal
ELDN stock soars to 52-week high, touches $3.35 amid surge - Investing.com
ELDN stock soars to 52-week high, touches $3.35 amid surge By Investing.com - Investing.com South Africa
Financial Analysis: Eledon Pharmaceuticals (NASDAQ:ELDN) & ABVC BioPharma (NASDAQ:ABVC) - Defense World
IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, - openPR
Eledon Pharmaceuticals completes $4 million equity sale - Investing.com India
Eledon Pharmaceuticals completes $4 million equity sale By Investing.com - Investing.com South Africa
Nantahala Capital Management LLC Invests $1.58 Million in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Nantahala Capital Management LLC Acquires New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - MarketBeat
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Update - MarketBeat
Midday Stock Roundup: STAAR Surgical CO. Shares Surge 22% - Orange County Business Journal
Eledon Pharmaceuticals initiates $75 million stock sale agreement By Investing.com - Investing.com Australia
Eledon Pharmaceuticals initiates $75 million stock sale agreement - Investing.com
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference - GlobeNewswire
ELDNEledon Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Eledon Announces Completion of Enrollment in Phase 2 BESTOW - GlobeNewswire
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients - StockTitan
Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Declines By 6.8% - MarketBeat
Analysts Issue Forecasts for Eledon Pharmaceuticals, Inc.'s Q3 2024 Earnings (NASDAQ:ELDN) - MarketBeat
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Expected to Earn Q3 2024 Earnings of ($0.20) Per Share - Defense World
Vanguard Group Inc. Has $2 Million Stock Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - MarketBeat
S&P 500 Information Technology [Sector] (SRIT) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Consumer Discretionary Capped Index (TTCD) QuotePress Release - The Globe and Mail
2 'Strong Buy'-Rated Stocks That Wall Street Believes Can Soar Over 360% - TradingView
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
Eledon Pharmaceuticals Inc (ELDN-Q) QuotePress Release - The Globe and Mail
Eledon Expects to Restate Results, Delays Quarterly Report - MarketWatch
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results - GlobeNewswire
Eledon Pharmaceuticals (NASDAQ:ELDN) Stock Price Down 1.7% - MarketBeat
Eledon Pharmaceuticals (NASDAQ:ELDN) Shares Down 1.7% - Defense World
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial - GlobeNewswire
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection - Yahoo Finance
Midday Stock Roundup: BJ’s Drops on Revenue Miss - Orange County Business Journal
4 High-Risk, High-Reward Small-Cap Stocks to Play the Rotation - Investing.com
Eledon Pharmaceuticals Inc (ELDN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):